ARUXF
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | 0.00 | $2M | $2M |
| 2025 Q4 | -0.01 | $1M | -$4M |
| 2024 Q2 | -0.01 | $120,000 | -$1M |
| 2024 Q4 | -0.01 | $682,000 | -$3M |
| 2023 Q2 | -0.01 | $4M | -$2M |
| 2023 Q4 | 0.01 | $7M | $2M |
| 2022 Q2 | -0.01 | $1M | -$1M |
| 2022 Q4 | -0.02 | $1M | -$5M |